Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Virtual Key Opinion Leader Event Scheduled For November 20
HC Wainwright & Co. analyst Oren Livnat reiterates Acasti Pharma (NASDAQ:ACST) with a Buy and maintains $12 price target.
Craig-Hallum analyst Chase Knickerbocker maintains Acasti Pharma (NASDAQ:ACST) with a Buy and raises the price target from $...
Acasti Pharma (NASDAQ:ACST) reported quarterly losses of $(0.21) per share. This is a 59.62 percent increase over losses of $(0...
Craig-Hallum analyst Chase Knickerbocker initiates coverage on Acasti Pharma (NASDAQ:ACST) with a Buy rating and announces P...
